What is the burden of axillary disease after neoadjuvant therapy in women with locally advanced breast cancer

Current Oncology

Volumn 20, Issue 2, 2013, Pages 111-117

  Cox, Christopher ^a   Holloway, C M ^b   Shaheta, A ^c   Nofech Mozes, S ^b   Wright, F C ^b  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Axillary lymph node dissection; Locally advanced breast cancer; Lymph node metastases; Neoadjuvant therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EOSIN; EPIRUBICIN; FLUOROURACIL; HEMATOXYLIN; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT;

EID: 84875905444     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1214     Document Type: Article

References (22)

1. Olivotto IA, Chua B, Allan SJ, Speers CH, Chia S, Ragaz J. Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer. J Clin Oncol 2003;21:851-4.
2. Seidman H, Gelb SK, Silverberg E, LaVerda N, Lubera JA. Survival experience in the Breast Cancer Detection Demonstration Project. CA Cancer J Clin 1987;37:258-90.
3. Reintgen D, Cox C, Greenberg H, et al. The medical legal implications of following mammographic breast masses. Am Surg 1993;59:99-105.
4. McCready DR, Hortobagyi GN, Kau SW, Smith TL, Buzdar AU, Balch CM. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surgery 1989;124:21-5.
5. Chung A, Giuliano A. Axillary staging in the neoadjuvant setting. Ann Surg Oncol 2010;17:2401-10.
6. Mamounas EP. Sentinel lymph node biopsy after neoadjuvant systemic therapy. Surg Clin North Am 2003;83:931-42.
7. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9.
8. Zambetti M, Mansutti M, Gomez P, et al. Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to er status, in two parallel, randomized phase ii trials with an adaptive design (ecto ii). Breast Cancer Res Treat 2012;132:843-51.
9. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in her2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010;28:2024-31.
10. Wright FC, Zubovits J, Gardner S, et al. Optimal assessment of residual disease after neo-adjuvant therapy for locally advanced and inflammatory breast cancer-clinical examination, mammography or magnetic resonance imaging J Surg Oncol 2010;101:604-10.
11. Chung MH, Ye W, Giuliano AE. Role for sentinel lymph node dissection in the management of large (> or +5 cm) invasive breast cancer. Ann Surg Oncol 2001;8:688-92.
12. Classe JM, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of GanglionSentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 2009;27:726-32.
13. Ozmen V, Unal ES, Muslumanoglu ME, et al. Axillary sentinel node biopsy after neoadjuvant chemotherapy. Eur J Surg Oncol 2010;36:23-9.
14. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer-Verlag; 2009: 432-3.
15. Cohen LF, Breslin TM, Kuerer HM, Ross MI, Hunt KK, Sahin AA. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol 2000;24:1266-72.
16. Chen ZL, Wen DR, Coulson WF, Giuliano AE, Cochran AJ. Occult metastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and histologic examination and conventional histology. Dis Markers 1991;9:239-48.
17. Prognostic importance of occult axillary lymph node micro-metastases from breast cancers. International (Ludwig) Breast Cancer Study Group. Lancet 1990;335:1565-8.
18. Trojani M, de Mascarel I, Bonichon F, Coindre JM, Delsol G. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987;55:303-6.
19. Turner RR, Ollila DW, Stern S, Giuliano AE. Optimal histo-pathologic examination of the sentinel lymph node for breast cancer staging. Am J Surg Pathol 1999;23:263-7.
20. Zhang PJ, Reisner RM, Nangia R, Edge SB, Brooks JJ. Effectiveness of multiple-level sectioning in detecting axillary nodal micrometastasis in breast cancer. Arch Pathol Lab Med 1998;122:687-90.
21. Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999;230:72-8.
22. Bear HD, Anderson S, Brown A, et al. The effect of tumor response of adding sequential preoperative docetaxel to pre-operative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-74.